Lessee, Operating Lease, Liability, to be Paid, Year Two of Enlivex Therapeutics Ltd. from 30 Jun 2020 to 30 Jun 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary: Enlivex Therapeutics Ltd. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two in USD history and change rate from 30 Jun 2020 to 30 Jun 2025.
Enlivex Therapeutics Ltd. Lessee, Operating Lease, Liability, to be Paid, Year Two for the quarter ending 30 Jun 2025 was $147,000, a 24% decline year-over-year.
Source SEC data: View on sec.gov

Lessee, Operating Lease, Liability, to be Paid, Year Two, Quarterly (USD)

Lessee, Operating Lease, Liability, to be Paid, Year Two, YoY Quarterly Change (%)

Enlivex Therapeutics Ltd. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2025	$147,000	-$46,000	-24%	30 Jun 2025	6-K	29 Aug 2025	2025	Q2
Q4 2024	$125,000	-$234,000	-65%	31 Dec 2024	20-F	30 Apr 2025	2024	FY
Q2 2024	$193,000			30 Jun 2024	6-K	30 Aug 2024	2024	Q2
Q4 2023	$359,000	-$322,000	-47%	31 Dec 2023	20-F	30 Apr 2024	2023	FY
Q4 2022	$681,000			31 Dec 2022	20-F	10 Apr 2023	2022	FY
Q4 2020	$258,000			31 Dec 2020	20-F	30 Apr 2021	2020	FY
Q2 2020	$154,000			30 Jun 2020	6-K/A	13 Oct 2020	2020	Q2

* An asterisk sign (*) next to the value indicates that the value is likely invalid.